Matthieu Girod

Mablink Bioscience is a biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for oncology. The company's proprietary PSARlink platform utilizes hydrophilic polysarcosine-based linkers to improve the pharmacological properties of ADCs, enhancing their stability and therapeutic index while reducing off-target toxicity. Its lead candidate, MBK-103, is an ADC targeting Folate Receptor Alpha (FRα) designed for the treatment of ovarian cancer and other solid tumors. In October 2023, Mablink was acquired by Eli Lilly to bolster Lilly's oncology pipeline and expand its capabilities in the ADC space.